Site last updated:
December 2011
Cancer Services Forum currently has 1452 registered members
The Kennedy report: Appraising the value of innovation and other benefits
Share
In a podcast released by NICE around the time of the report, Sir Ian also talks about another recent development in the way drugs are approved for the NHS—namely patient access schemes. He refers to cancer at the end of life as having “elbowed its way onto the middle of the stage” particularly with reference to end-of-life provision, which he says “I think could well constitute a Trojan horse for the whole of NICE, unless it’s controlled”.
Needless to say, the Kennedy report and the Life Sciences Blueprint have created something of a stir. Here we have the reactions of Alison Clough, and those of Christopher McCabe, Tania Stafinski, Richard Edlin and Devidas Menon.
Comment from Alison Clough, ABPI
“Overall there are several positive recommendations in Professor Sir Ian Kennedy’s report. We welcome his acknowledgement that NICE processes need to change and that wider health-related benefits from medicines need to be taken, transparently, into account and also that innovation should be rewarded. However, industry would like a process where the ICER (incremental cost-effectiveness ratio) is not the principal determinant but is considered alongside these other benefits.”
Page 2 of 7
Taken from the Issue 9/September 2009 issue of Cancer Services Forum.
Click here to view the full issue.
Click here to view the full issue.
Discussion.